Bamlanivimab has been administered at doses of 7000 mg (ten times the authorized dose) during phase 2 clinical trials without any observed dose-limiting toxicity. In the event of an overdose, the recommended treatment is symptomatic and supportive measures; there is no antidote for bamlanivimab overdose.L20979
Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.A224039, L15311, L15316 Bamlanivimab is a neutralizing IgG1? mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.A224039, L15311, L15316, L20979
AbCellera initially discovered bamlanivimab in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), and subsequently further developed it in collaboration with Eli Lilly and Company. Bamlanivimab consists of two identical light chains of 214 amino acids and two identical heavy chains of 455 amino acids each; the Fc region is unmodified.L20979 Bamlanivimab is produced in Chinese Hamster Ovary (CHO) cells.L20979 Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.A224044, L20974 It is set to enter phase 3 clinical trials.L15316, L15321
Under the EUA granted in February 2021, bamlanivimab is used in combination with etesevimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:L40179 this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.L40174 The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.L40179
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Bamlanivimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bamlanivimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Bamlanivimab. |
| Estrone | Estrone may increase the thrombogenic activities of Bamlanivimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Bamlanivimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bamlanivimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Bamlanivimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Bamlanivimab. |
| Estriol | Estriol may increase the thrombogenic activities of Bamlanivimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Bamlanivimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bamlanivimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bamlanivimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bamlanivimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bamlanivimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bamlanivimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bamlanivimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bamlanivimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bamlanivimab. |
| Equol | Equol may increase the thrombogenic activities of Bamlanivimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bamlanivimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bamlanivimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bamlanivimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bamlanivimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Bamlanivimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Bamlanivimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Bamlanivimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Bamlanivimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bamlanivimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bamlanivimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Bamlanivimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bamlanivimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bamlanivimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bamlanivimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bamlanivimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bamlanivimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bamlanivimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bamlanivimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bamlanivimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bamlanivimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bamlanivimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bamlanivimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bamlanivimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bamlanivimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bamlanivimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bamlanivimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bamlanivimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bamlanivimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bamlanivimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bamlanivimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Bamlanivimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bamlanivimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bamlanivimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bamlanivimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bamlanivimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bamlanivimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bamlanivimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bamlanivimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bamlanivimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bamlanivimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bamlanivimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bamlanivimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bamlanivimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Bamlanivimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Bamlanivimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bamlanivimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bamlanivimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Bamlanivimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bamlanivimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Bamlanivimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Bamlanivimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Bamlanivimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Bamlanivimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Bamlanivimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Bamlanivimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Bamlanivimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Bamlanivimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Bamlanivimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Bamlanivimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Bamlanivimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Bamlanivimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Bamlanivimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Bamlanivimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Bamlanivimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bamlanivimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bamlanivimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Bamlanivimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Bamlanivimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bamlanivimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Bamlanivimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Bamlanivimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Bamlanivimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Bamlanivimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Bamlanivimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Bamlanivimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Bamlanivimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Bamlanivimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bamlanivimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Bamlanivimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Bamlanivimab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Bamlanivimab. |